Eisai's Perampanel Phase III Outcomes Show Efficacy, But May Not Meet Company Hype
This article was originally published in PharmAsia News
TOKYO - Eisai Co. Ltd. released generally positive results of a Phase III trial for epilepsy drug perampanel, a compound which the company has promoted heavily to investors and analysts, but discouraging results on dose-dependent efficacy may contribute to an underperformance of the hyped drug, according to a Tokyo pharma analyst
You may also be interested in...
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.
Eisai’s Fycompa becomes only the second drug with a new mechanism of action approved by FDA for epilepsy in the last decade.
Post-Aricept Patent Expiry, Eisai Starts Comeback With Roll-Out Of New Anti-Epileptic Fycompa In Europe
Eisai hopes the launch of its first-in-class anti-epileptic drug Fycompa in Britain and other European markets will help offset revenues lost after its Aricept Alzheimer’s therapy went off patent in the region earlier this year, and signal a new phase of growth for the Japanese company.